A detailed history of Bank Of America Corp transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 44,591 shares of ATNM stock, worth $65,548. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,591
Previous 41,571 7.26%
Holding current value
$65,548
Previous $307,000 72.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.72 - $8.0 $5,194 - $24,160
3,020 Added 7.26%
44,591 $83,000
Q2 2024

Aug 14, 2024

BUY
$6.56 - $9.89 $16,459 - $24,814
2,509 Added 6.42%
41,571 $307,000
Q1 2024

May 15, 2024

SELL
$5.0 - $9.2 $52,360 - $96,342
-10,472 Reduced 21.14%
39,062 $305,000
Q4 2023

Feb 14, 2024

BUY
$4.02 - $6.08 $9,832 - $14,871
2,446 Added 5.19%
49,534 $251,000
Q2 2023

Aug 14, 2023

SELL
$7.15 - $9.39 $70,720 - $92,876
-9,891 Reduced 17.36%
47,088 $349,000
Q1 2023

May 12, 2023

BUY
$8.51 - $14.26 $314,750 - $527,420
36,986 Added 184.99%
56,979 $538,000
Q4 2022

Feb 10, 2023

BUY
$7.05 - $14.41 $1,036 - $2,118
147 Added 0.74%
19,993 $212,000
Q3 2022

Nov 14, 2022

BUY
$4.81 - $8.48 $327 - $576
68 Added 0.34%
19,846 $147,000
Q1 2022

May 16, 2022

SELL
$4.57 - $6.4 $18,855 - $26,406
-4,126 Reduced 17.26%
19,778 $101,000
Q4 2021

Feb 08, 2022

BUY
$6.01 - $8.8 $24,009 - $35,156
3,995 Added 20.07%
23,904 $144,000
Q3 2021

Nov 15, 2021

BUY
$5.76 - $9.67 $114,439 - $192,123
19,868 Added 48458.54%
19,909 $176,000
Q2 2021

Sep 13, 2021

BUY
$7.01 - $8.63 $287 - $353
41 New
41 $0

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $37M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.